|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM37331972X |
| 003 |
DE-627 |
| 005 |
20240726232441.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240608s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202401960
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1482.xml
|
| 035 |
|
|
|a (DE-627)NLM37331972X
|
| 035 |
|
|
|a (NLM)38843807
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chen, Hangwei
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a DNA Framework-Enabled 3D Organization of Antiarrhythmic Drugs for Radiofrequency Catheter Ablation
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.07.2024
|
| 500 |
|
|
|a Date Revised 25.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Preorganizing molecular drugs within a microenvironment is crucial for the development of efficient and controllable therapeutic systems. Here, the use of tetrahedral DNA framework (TDF) is reported to preorganize antiarrhythmic drugs (herein doxorubicin, Dox) in 3D for catheter ablation, a minimally invasive treatment for fast heartbeats, aiming to address potential complications linked to collateral tissue damage and the post-ablation atrial fibrillation (AF) recurrence resulting from incomplete ablation. Dox preorganization within TDF transforms its random distribution into a confined, regular spatial arrangement governed by DNA. This, combined with the high affinity between Dox and DNA, significantly increases local Dox concentration. The exceptional capacity of TDF for cellular internalization leads to a 5.5-fold increase in intracellular Dox amount within cardiomyocytes, effectively promoting cellular apoptosis. In vivo investigations demonstrate that administering TDF-Dox reduces the recurrence rate of electrical conduction after radiofrequency catheter ablation (RFCA) to 37.5%, compared with the 77.8% recurrence rate in the free Dox-treated group. Notably, the employed Dox dosage exhibits negligible adverse effects in vivo. This study presents a promising treatment paradigm that strengthens the efficacy of catheter ablation and opens a new avenue for reconciling the paradox of ablation efficacy and collateral damage
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Dox delivery
|
| 650 |
|
4 |
|a atrial fibrillation
|
| 650 |
|
4 |
|a radiofrequency catheter ablation
|
| 650 |
|
4 |
|a tetrahedral DNA framework
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 650 |
|
7 |
|a Anti-Arrhythmia Agents
|2 NLM
|
| 650 |
|
7 |
|a DNA
|2 NLM
|
| 650 |
|
7 |
|a 9007-49-2
|2 NLM
|
| 700 |
1 |
|
|a Li, Fan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ge, Yulong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Junyi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Xing, Xing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Min
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ge, Zhilei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zuo, Xiaolei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fan, Chunhai
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Shaopeng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Fang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 30 vom: 11. Juli, Seite e2401960
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:30
|g day:11
|g month:07
|g pages:e2401960
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202401960
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 30
|b 11
|c 07
|h e2401960
|